Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells

Abstract Background Glioblastoma (GBM) is an aggressive brain tumor with universal recurrence and poor prognosis. The recurrence is largely driven by chemoradiation resistant cancer stem cells (CSCs). Epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are amplified in ~ 60% and ~ 30% of...

Full description

Bibliographic Details
Main Authors: Raghupathy Vengoji, Muzafar A. Macha, Rama Krishna Nimmakayala, Satyanarayana Rachagani, Jawed A. Siddiqui, Kavita Mallya, Santhi Gorantla, Maneesh Jain, Moorthy P. Ponnusamy, Surinder K. Batra, Nicole Shonka
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Temozolomide
Afatinib
Glioblastoma
Cancer stem cells
Epidermal growth factor receptor
Online Access:http://link.springer.com/article/10.1186/s13046-019-1264-2

Internet

http://link.springer.com/article/10.1186/s13046-019-1264-2

Similar Items